`571-272-7822 Entered: January 8, 2019
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`_______________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`_______________
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`v.
`SANOFI-AVENTIS DEUTSCHLAND GMBH,
`Patent Owner.
`
`_______________
`Case IPR2017-01526 (Patent 7,476,652 B2)
`Case IPR2017-015281 (Patent 7,713,930 B2)
`________________
`
`Before ERICA A. FRANKLIN, ROBERT A. POLLOCK, and
`MICHELLE N. ANKENBRAND, Administrative Patent Judges.
`ANKENBRAND, Administrative Patent Judge.
`
`
`
`
`ORDER
`Granting Patent Owner’s Motion to Seal
`37 C.F.R. § 42.54
`
`
`
`
`1 This Order pertains to both noted proceedings. We exercise our discretion to
`issue a single Order for entry in each proceeding. The parties are not authorized to
`use this style heading for subsequent papers without prior Board approval.
`
`
`
`IPR2017-01526 (Patent 7,476,652 B2)
`IPR2017-01528 (Patent 7,713,930 B2)
`
`
`INTRODUCTION
`On December 12, 2018, we entered a Final Written Decision (Paper 89,2
`“Final Decision” or “Final Dec.”) in each of the above-referenced proceedings.
`In each Final Decision, we denied Petitioner’s motion to seal portions of its sur-
`sur-reply that reference Exhibits 2065–2069 without prejudice to Patent Owner.
`Final Dec. 47. Although Petitioner represented that Patent Owner had designated
`the information Petitioner requested to seal confidential, we determined that
`Petitioner failed to provide good cause for sealing the information. Id. However,
`we authorized Patent Owner to file a motion to seal that information in Petitioner’s
`sur-sur-reply. Id.
`On December 20, 2017, Patent Owner filed a Motion to Seal (Paper 93,
`“Motion”). In the Motion, Patent Owner requests to seal the portions of
`Petitioner’s sur-sur-reply that Petitioner requested to seal in the motion we denied
`and requests that we approve the redactions in the publicly-filed version of
`Petitioner’s sur-sur-reply (Paper 88) that the parties’ jointly prepared. Id. at 1.
`Patent Owner also requests that we approve the sealed and public versions of its
`updated exhibit list (Papers 91, 92). Id.
`We grant the motion for the reasons set forth below.
`
`DISCUSSION
`“There is a strong public policy for making all information filed in a quasi-
`judicial administrative proceeding open to the public, especially in an inter partes
`review which determines the patentability of claims in an issued patent and
`therefore affects the rights of the public.” Garmin Int’l v. Cuozzo Speed Techs.,
`
`
`2 Unless otherwise noted, citations are to the papers and exhibits filed in
`IPR2017-01526.
`
`
`
`2
`
`
`
`IPR2017-01526 (Patent 7,476,652 B2)
`IPR2017-01528 (Patent 7,713,930 B2)
`
`LLC, IPR2012–00001, slip op. at 1–2 (PTAB Mar. 14, 2013) (Paper 34). For this
`reason, except as otherwise ordered, the record of an inter partes review trial shall
`be made available to the public. See 35 U.S.C. § 316(a)(1); 37 C.F.R. § 42.14.
`The standard for granting a motion to seal is good cause. 37 C.F.R. § 42.54. That
`standard includes a showing that “(1) the information sought to be sealed is truly
`confidential, (2) a concrete harm would result upon public disclosure, (3) there
`exists a genuine need to rely in the trial on the specific information sought to be
`sealed, and (4) on balance, an interest in maintaining confidentiality outweighs the
`strong public interest in having an open record.” Argentum Pharms. LLC v. Alcon
`Research, Ltd., Case IPR2017-01053, slip op. at 4 (Paper 27) (PTAB Jan. 19,
`2018) (informative).
`Patent Owner asserts that Petitioner’s sur-sur-reply and Patent Owner’s
`updated exhibits list contain confidential information and that Patent Owner would
`suffer concrete harm if the information was publicly disclosed. Mot. 3. In
`particular, Patent Owner represents that Petitioner’s sur-sur-reply “summarizes and
`quotes confidential submissions made by Hoechst Marion Roussel to, and records
`of correspondence with, the FDA regarding the approval of its insulin glargine
`product.” Id. Patent Owner further states that the sur-sur-reply “summarizes
`confidential and proprietary research and development, testing procedures,
`analyses and results regarding [Patent Owner’s] Lantus [product]” and that the
`updated exhibit list “refers to and describes now sealed EX2065–EX2069.” Id.
`(noting further that the sur-sur-reply and updated exhibit list refer to research,
`development, testing, clinical, manufacturing, packaging, and pharmacological
`information). Petitioner did not oppose the Motion.
`After having considered the Motion and Patent Owner’s representations
`therein, we determine Patent Owner establishes good cause for sealing the
`
`
`
`3
`
`
`
`IPR2017-01526 (Patent 7,476,652 B2)
`IPR2017-01528 (Patent 7,713,930 B2)
`
`requested information. Patent Owner demonstrates that the information it seeks to
`seal consists of confidential and proprietary research and development information,
`confidential packaging specifications, confidential regulatory submissions, and
`confidential commercial information. And we see little harm to the public’s
`interest in restricting access to the information because we did not rely on any
`confidential information in the Final Decision. Also, the public versions of
`Petitioner’s sur-sur-reply and Patent Owner’s updated exhibit list appear to redact
`only the information that Patent Owner seeks to seal in in each Motion.
`We further note that the record of each proceeding shall be preserved in its
`entirety and that no sealed document will be expunged or made public, pending the
`outcome of any appeal taken from the Final Decision. The sealed documents may
`be made public at the conclusion of any appeal. See Office Patent Trial Practice
`Guide, 77 Fed. Reg. 48,756, 48,761 (Aug. 14, 2012). At that time, either party
`may file a motion to expunge the sealed documents from the record pursuant to
`37 C.F.R. § 42.56.
`
`ORDER
`
`It is
`ORDERED that Patent Owner’s Motion to Seal in each proceeding
`(IPR2017-01526 Paper 93; IPR2017-01528 Paper 91) is granted.
`
`
`
`
`
`4
`
`
`
`IPR2017-01526 (Patent 7,476,652 B2)
`IPR2017-01528 (Patent 7,713,930 B2)
`
`PETITIONER:
`
`Jeffrey Guise
`Douglas Carsten
`Richard Torczon
`Lorelei Westin
`Clark Lin
`Nancy Zhang
`Alina Litoshyk
`Nicole W. Stafford
`WILSON SONSINI GOODRICH & ROSATI
`jguise@wsgr.com
`dcarsten@wsgr.com
`rtorczon@wsgr.com
`lwestin@wsgr.com
`clin@wsgr.com
`nzhang@wsgr.com
`alitoshyk@wsgr.com
`nstafford@wsgr.com
`
`PATENT OWNER:
`
`Elizabeth Weiswasser
`Anish Desai
`Aaron Pereira
`WEIL, GOTSHAL & MANGES LLP
`elizabeth.weiswasser@weil.com
`anish.desai@weil.com
`aaron.pereira@weil.com
`
`
`
`5
`
`